| Literature DB >> 24824074 |
Maria Laura Bertolaccini1, Olga Amengual2, Laura Andreoli3, Tatsuya Atsumi2, Cecilia B Chighizola4, Ricardo Forastiero5, Philip de Groot6, Gabriella Lakos7, Marc Lambert8, Pierluigi Meroni9, Thomas L Ortel10, Michelle Petri11, Anisur Rahman12, Robert Roubey13, Savino Sciascia14, Melissa Snyder15, Anne E Tebo16, Angela Tincani3, Rohan Willis17.
Abstract
Current classification criteria for definite Antiphospholipid Syndrome (APS) require the use of three laboratory assays to detect antiphospholipid antibodies (aCL, anti-β2GPI and LA) in the presence of at least one of the two major clinical manifestations (i.e. thrombosis or pregnancy morbidity) of the syndrome. However, several other autoantibodies shown to be directed to other proteins or their complex with phospholipids have been proposed to be relevant to APS but their clinical utility and their diagnostic value remains elusive. This report summarizes the findings, conclusions and recommendations of the "APS Task Force 3-Laboratory Diagnostics and Trends" meeting that took place during the 14th International Congress on Antiphospholipid Antibodies (APLA 2013, September 18-21, Rio de Janeiro, RJ, Brazil).Entities:
Keywords: Antiprothrombin antibodies; Domain I; IgA; Lupus anticoagulant; Risk; aCL
Mesh:
Substances:
Year: 2014 PMID: 24824074 DOI: 10.1016/j.autrev.2014.05.001
Source DB: PubMed Journal: Autoimmun Rev ISSN: 1568-9972 Impact factor: 9.754